Interestingly, AGR2 is the major gene highly correlated with the survival rate and sorafenib resistance in liver cancer; however, the relationship between AGR2 and sorafenib treatment in HCC has not been demonstrated. This evidence concerns the gene AGR2 and liver cancer.